CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Cardiac Complications of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy.
Cardiac Complications of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
免疫检查点抑制剂和CAR-T 细胞疗法彻底改变了癌症治疗,但可能通过免疫相关不良事件导致危及生命的心血管毒性。心肌炎是免疫检查点抑制剂最常见且可能致命的毒性。T细胞疗法可能导致细胞因子释放综合征(CRS)。诊断免疫检查点抑制剂相关心肌炎需要采用多模态方法,包括生物标志物、影像学和心内膜心肌活检;CRS则表现为类似分布性休克的临床综合征。管理措施包括停用致病治疗,对免疫检查点抑制剂相关心肌炎使用皮质类固醇进行免疫抑制,并对CRS使用白细胞介素6拮抗剂。肿瘤科医生与心脏科医生协作,对于早期识别和及时治疗至关重要。
Immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy have revolutionized cancer treatment but can cause life-threatening cardiovascular toxicities through immune-related adverse events. Myocarditis is the most common and potentially fatal toxicity with immune checkpoint inhibitors. T-cell therapies can potentially lead to cytokine release syndrome.
Diagnosis of ICI-myocarditis requires a multimodal approach, including biomarkers, imaging, and endomyocardial biopsy, while CRS is characterized by a clinical syndrome resembling distributive shock. Management involves discontinuing the offending therapy, immunosuppression with corticosteroids for ICI-myocarditis, and interleukin-6 antagonists for CRS. Collaboration between oncologists and cardiologists is crucial for early recognition and prompt treatment.
MEMBER ACCOUNT
登录成功会直接打开下一页。